Non-Sponsored
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
This life-threatening pediatric disease can cause sideroblastic anemia, metabolic crisis, and bone marrow failure.
Cemiplimab + isatuximab combo shows 51% CR and promising safety in R/R ENKTL, exceeding study endpoint.
Novel PI3Kδ + HDACi combo shows promise for relapsed/refractory CTCL, with favorable outcomes and manageable safety.
The MZL cohort of a phase 2 study saw the most success from the atezolizumab plus obinutuzumab and venetoclax regimen.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
In an era of progress, one of the next goal posts is successful development of trispecifics.
Measles cases are the highest in 33 years, with more than 1,000 cases reported in 2025 as of July.
From Buffalo to the Manhattan borough, Dr. Rampal shares his journey to becoming a hematologist-oncologist.
Michael Styler, MD, received the NCCN 2025 Outstanding Contributor Award for his commitment to improving cancer care.
Glofitamab combos show high, durable responses in high-risk LBCL, per phase II COALITION trial in younger patients.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
As director of the FDA’s CBER, Dr. Prasad oversaw the regulation of biological products for human use.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
A post-hoc analysis of long-term results in the AGILE trial adds to promising initial efficacy and safety results.
Blood Cancers Today editors Krina Patel and Rahul Banerjee reflect on paradigm-shifting myeloma research from ASCO.
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
The experts focused on cilta-cel when comparing the three FDA-approved treatments' efficacies, toxicities, and availability.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.